Chronic obstructive pulmonary disease (COPD) is a common respiratory disease featuring persistent respiratory symptoms and progressive airflow limitation. Long-acting muscarinic antagonists (LAMAs) are the mainstays of therapy for symptom improvement in COPD. LAMA may induce urinary tract infections (UTIs), but they are under-recognized complications and may be associated with disease progression in patients with COPD. This study aimed to determine whether LAMAs-containing treatment modifies the risk of UTIs in COPD.
